ARS Pharmaceuticals annual return on equity
2022
2023
2024
2025
ARS Pharmaceuticals Return on Equity (ROE) Growth & History (SPRY)
ARS Pharmaceuticals's return on equity was −92.33% for fiscal 2025.
View full ARS Pharmaceuticals company overviewARS Pharmaceuticals annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −92.33% | −95.61 pp |
| 2024 | 2024-12-31 | 3.28% | +24.87 pp |
| 2023 | 2023-12-31 | −21.59% | +7.12 pp |
| 2022 | 2022-12-31 | −28.71% | — |
ARS Pharmaceuticals quarterly return on equity
Q1.21
Q2.21
Q3.21
Q4.21
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −168.89% | −147.59 pp |
| Q1 2026 | 2026-03-31 | −69.05% | −55.08 pp |
| Q4 2025 | 2025-12-31 | −31.56% | −53.37 pp |
| Q3 2025 | 2025-09-30 | −30.09% | −20.90 pp |
| Q2 2025 | 2025-06-30 | −21.31% | −15.61 pp |
| Q1 2025 | 2025-03-31 | −13.97% | −9.45 pp |
| Q4 2024 | 2024-12-31 | 21.82% | +24.88 pp |
| Q3 2024 | 2024-09-30 | −9.19% | −3.07 pp |
| Q2 2024 | 2024-06-30 | −5.70% | +1.12 pp |
| Q1 2024 | 2024-03-31 | −4.53% | +1.08 pp |
| Q4 2023 | 2023-12-31 | −3.06% | +9.89 pp |
| Q3 2023 | 2023-09-30 | −6.12% | — |
| Q2 2023 | 2023-06-30 | −6.82% | — |
| Q1 2023 | 2023-03-31 | −5.60% | — |
| Q4 2022 | 2022-12-31 | −12.96% | −43.39 pp |
| Q4 2021 | 2021-12-31 | 30.43% | — |
| Q3 2021 | 2021-09-30 | −6.65% | — |
| Q2 2021 | 2021-06-30 | −6.82% | — |
| Q1 2021 | 2021-03-31 | −5.02% | — |
ARS Pharmaceuticals return on equity trends
Between the periods ended 2022-12-31 and 2025-12-31, ARS Pharmaceuticals's return on equity decreased from −28.71% to −92.33%, a change of −63.62 percentage points. The latest reported quarter, Q2 2026, shows −168.89%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review ARS Pharmaceuticals source filings ↗